Univfy and PracticeHwy Announce Partnership to Expand Access to Artificial Intelligence/Machine Learning Platform for Fertility Providers and Patients – Yahoo Finance

SAN FRANCISCO BAY AREA, Calif. and IRVING, Texas, Jan. 25, 2022 /PRNewswire/ — Univfy, a global leader in using artificial intelligence (AI) and machine learning (ML) to personalize counseling and increase access to fertility care, announced today a strategic partnership with PracticeHwy's electronic medical records solution, eIVF, a pioneer in the fertility industry and a portfolio company of Atlantic Street Capital "ASC". The goal of the partnership is to bring a higher level of insight to fertility care by making fertility treatments more affordable, predictable, and successful, while supporting growth of the fertility market.
Univfy's highly scalable AI/ML platform delivers validated IVF success prediction models using each fertility center's own data to support more effective patient counseling. Patients counseled with the Univfy Report are 2-3 times more likely to use their doctor's recommended treatment, maximizing their chances of having a healthy baby. The partnership with eIVF will support data transmission between the Univfy AI Platform and the EMR, enabling easy and automated generation of the Univfy PreIVF Report and suite of Univfy AI/ML-assisted tools.
"This partnership with eIVF will accelerate and automate generation of Univfy reports at the point of care, making the reports accessible to many more fertility patients," said Mylene Yao, CEO and Cofounder of Univfy. "Providers have been asking for the Univfy AI/ML products to become a standard part of patient care. Patients and providers value having transparency, personalization, and accuracy regarding their IVF success rates, so that they can make the best decisions about their treatment."
"PracticeHwy's collaboration with Univfy furthers our commitment to clients to grow eIVF's suite of offerings with innovative partners," said Nimesh Shah, PracticeHwy CEO. "We are excited that our partnership will create a streamlined experience for eIVF's growing network of fertility centers by providing an easier and more efficient workflow for physicians and their teams."
One in eight, or 7 million, reproductive age couples in the US and more than 80 million couples worldwide struggle to conceive on their own. IVF is the most effective treatment for most women and couples, but it is vastly underutilized, most likely due to financial risk and physical and emotional stress. The Univfy AI Platform is designed to meet the medical, emotional, and financial needs of fertility patients.
Last month, Univfy announced that it raised $6 million of its Series B funding round, which will enable expanded access of Univfy AI/ML services to more patients through fertility centers, employers, benefits programs and health plans.
About Univfy
Univfy makes fertility care more affordable, successful, and predictable for women and couples navigating their family-building options. Combining technology and expert client support, we provide our scientifically validated AI platform, actionable business insights and financial modeling to help fertility centers grow. Univfy's transparent and personalized counseling reports empower patients with personalized information and counseling to inform smarter spending and decision-making. Based on proprietary technology developed at Stanford University, Univfy uses a rigorous scientific process to develop and validate prediction models to support patient counseling at fertility centers. Our methods have been published in top, peer-reviewed research publications. Univfy's personalized prognostics enables fertility centers to offer patients value-based pricing programs that cap financial risk for patients and make multiple IVF cycles more affordable. Univfy is commercialized in the US, Canada, and EU. Univfy's compliance includes HIPAA and GDPR. We have a global IP portfolio. The Univfy PreIVF Report is CE-marked as a medical device software in the EU. Visit www.univfy.com for more information.
About PracticeHwy
PracticeHwy is a leader in healthcare software which serves over 140 fertility practices and clinics worldwide. In 2002, they launched eIVF, one of the first electronic medical record (EMR) platforms focused on Reproductive Endocrinology and Infertility (REI) practices. Since then, eIVF has supported data entry for over a million cycles. Known for its pursuit of excellence in the fertility industry, PracticeHwy.com has seen a consistent growth trajectory throughout the years by continuously developing innovative solutions which support all aspects of a fertility center's operations. For more information on eIVF, visit www.eivf.org.
About Atlantic Street Capital
ASC is a private equity firm that invests in lower middle market companies poised for the next level of growth. The firm targets entrepreneurial management partners and fundamentally sound companies between $4 million and $25 million of EBITDA that will benefit from capital investment and ASC's value-added strategic and operational support. As a result, ASC works closely with management to unlock their business' underlying value and help them succeed. For more information, visit www.atlanticstreetcapital.com.
Contact Univfy
Investors: investor@univfy.com
Heather Holland
Director of Communications
Tel: +1 (646) 400-2745
Contact eIVF
Jera Sangworn
Director of Marketing and Communications
Tel: +1 (469) 472-9891
View original content to download multimedia:https://www.prnewswire.com/news-releases/univfy-and-practicehwy-announce-partnership-to-expand-access-to-artificial-intelligencemachine-learning-platform-for-fertility-providers-and-patients-301467078.html
SOURCE Univfy Inc.
(Bloomberg) — Jeremy Grantham got the market’s attention with his “super bubble” call on U.S. stocks. Now he wants to get an even more alarming and urgent message out, one his critics may find harder to accept. Most Read from BloombergStock Rebound Fails and Futures Plunge on Earnings: Markets WrapMark Zuckerberg’s Stablecoin Ambitions Unravel With Diem Sale TalksNvidia Quietly Prepares to Abandon $40 Billion Arm BidA Nor’easter Approaching New York Risks Becoming a Bomb CycloneStocks Storm Bac
Markets have reeled since the Federal Reserve announced, through the release of the December minutes, that the central bank would like to take a big whack at its $9 trillion balance sheet rather than keep it at that lofty level. Value stocks, they argue, will continue to be boosted by the transition from quantitative easing to quantitative tightening, as the Fed pivots from fighting deflation to fighting inflation. By and large, the Goldman team says most of the moves in the market have been explained by fundamentals, but it says some defensive sectors, including food and beverages, household goods and personal products, may have rerated too much, while semiconductors may have sold off by too much.
Yahoo Finance Live's Julie Hyman and Brian Sozzi discuss fourth quarter earnings for Boeing and how the stock is reacting.
These two clinical-stage biotechs have major upcoming catalysts that could catapult their shares higher.
Peloton (NASDAQ: PTON) stock is in a world of hurt in recent months. The interactive exercise equipment maker initially cut the price of one of its popular products by $400 and is now reversing course and increasing prices. Only a couple of quarters ago, Peloton announced it would be reducing the price of its Bikes by $400.
Technology stocks have continued to see heavy selling activity in 2022. Cathie Wood has been buying the dip in three names in particular.
Every investor in Alibaba Group Holding Limited ( NYSE:BABA ) should be aware of the most powerful shareholder groups…
On yet another "red" day for stock markets, marijuana investors saw their stocks tumble right along with the rest of the Nasdaq. In a press release early this morning, Hexo gave investors an update on its strategic plan entitled "The Path Forward," explaining how Hexo — shares of which traded above $30 just a couple of years ago, but now fetch just $0.50 — intends to regain its mojo and get its share price moving higher once again. New product launches appear key to Hexo's plan, as the company launches sales of a "transdermal cream and a CBD-forward body lotion," and also a new line of "gummy confection called Redebles."
Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett is one of the world's greatest investors. Between Dec. 31, 1964 and Dec. 31, 2021, he oversaw the creation of more than $600 billion in market value and led Berkshire's Class A shares (BRK.A) to aggregate gains in excess of 3,600,000%! Of the more than three-dozen securities Berkshire Hathaway owns in its $350 billion investment portfolio, three stand out as wholly avoidable in 2022.
A lawyer helped us create a “cohabitation agreement” for our house purchase. If things go well, my current company of five years could IPO and make me a multi-millionaire. A cohabitation agreement is smart, especially if you own a home together.
Yahoo Finance Live's Emily McCormick and Adam Shapiro break down several of the trending stocks attempting to correct themselves during this volatile trading week.
Elon Musk has been driving Telsa's new Cybertruck and he thinks it's 'awesome.' An electric truck opens a substantial new market for Tesla.
After a promising start, General Electric (NYSE: GE) spent most of the last year in sideways movement as the reverse stock split in August and the announced 3-way breakup of the company in November did little to improve the sentiment. Yet, as uncertainty about the overall market grows, turnaround stories like GE bring on increased risks. View our latest analysis for General Electric
Recent market volatility is enough to make your head spin, and can cause plenty of confusion for retail investors seeking a solid market strategy. It’s tempting to look to the experts, but that raises another question: which experts are the best to follow? Probably the best experts to follow are the corporate insiders. These are company officers, in upper management or the Board of Directors, who have both direct access to their company’s inner workings and a responsibility to their shareholders
Gilead Sciences, which sold the drug for $3 million less than three years ago, still could come out a winner if the drug is approved by the FDA for patients with the blood cancer myelofibrosis.
Clorox (NYSE: CLX) is one dividend-paying company that thrived at the pandemic onset as folks urgently looked for disinfectant products. The rest of Clorox's product portfolio also performed well as most of them are used at home, and people have been spending a lot more time there. In the beginning of Clorox's fiscal year 2022, sales are decreasing slightly as the fear of contracting COVID-19 diminishes.
Despite supply chain headwinds that have plagued the global auto industry at an unprecedented scale, Tesla has whimsically navigated recent disruptions to post blowout delivery and production numbers as demand for electric vehicles soars.
Stocks gained Wednesday morning to shake off some losses after a couple of volatile session on Wall Street. Investors looked to the Federal Reserve's latest statement and press conference to remove some uncertainty on the outlook for monetary policy.
AT&T's fourth-quarter profit topped expectations, even as its outlook disappointed. The market doesn't seem to mind.
Yahoo Finance's Jared Blikre examines Microsoft's after-hours trading. Greg Swenson, Brigg Macadam Founding Partner, and John Kicklighter, DailyFX Chief Strategist, provide additional commentary on Microsoft's earnings during a volatile market.

Connect with Chris Hood, a digital strategist that can help you with AI.

Leave a Reply

Your email address will not be published.

© 2022 AI Caosuo - Proudly powered by theme Octo